OncoMatch/Clinical Trials/NCT05546723
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Is NCT05546723 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Autologous CAR-T cell therapy expressing the BAFF-ligand. for multiple myeloma, refractory.
Treatment: Autologous CAR-T cell therapy expressing the BAFF-ligand. — Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory agent
relapsed or refractory after 3 or more lines of therapy including an immunomodulatory agent
Must have received: proteasome inhibitor
relapsed or refractory after 3 or more lines of therapy including ... a proteasome inhibitor
Must have received: anti-CD38 antibody
relapsed or refractory after 3 or more lines of therapy including ... an anti-CD38 antibody
Cannot have received: autologous stem cell transplant
Exception: within 6 weeks of informed consent
ASCT within 6 weeks of informed consent
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Cannot have received: investigational agent
Exception: less than 28 days elapsed between prior treatment and lymphocyte collection
Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection
Lab requirements
Kidney function
Serum creatinine < 2 mg/dL
Liver function
Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome); AST (SGOT)/ALT ≤ 2.5 X institutional upper limit of normal
Cardiac function
Cardiac ejection fraction of >45%, and no evidence of pericardial effusion, as determined by an echocardiogram
Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome). AST (SGOT)/ALT ≤ 2.5 X institutional upper limit of normal. Serum creatinine < 2 mg/dL. Cardiac ejection fraction of >45%, and no evidence of pericardial effusion, as determined by an echocardiogram. Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Seidman Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify